{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:51:18Z","timestamp":1787925078411,"version":"build-2784847793"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA-221813"],"award-info":[{"award-number":["R01-CA-221813"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01-AR-080946"],"award-info":[{"award-number":["R01-AR-080946"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006928","name":"Ohio State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012482","name":"University of Michigan Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100012482","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01-HL-157453"],"award-info":[{"award-number":["R01-HL-157453"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.lfs.2025.123595","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T01:52:23Z","timestamp":1743385943000},"page":"123595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["SiRNA-mediated knockdown of TOP2B protects hiPSC-derived cardiomyocytes from doxorubicin-induced toxicity"],"prefix":"10.1016","volume":"371","author":[{"given":"Neha","family":"Saroj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj Singh","family":"Dholaniya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Baseeruddin","family":"Alvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Sridharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navisha","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Abdullah","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayza","family":"Choudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf Ali","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Kathleen","family":"Mikula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinender Kumar","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2025.123595_bb0005","first-page":"214","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment, Curr","volume":"7","author":"Volkova","year":"2011","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.lfs.2025.123595_bb0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.lfs.2025.123595_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076676","article-title":"Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells","volume":"8","author":"Vavrova","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2025.123595_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.847012","article-title":"Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection","volume":"9","author":"Morelli","year":"2022","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.lfs.2025.123595_bb0025","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2025.123595_bb0030","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/01913129409016291","article-title":"Assessment of anthracycline cardiomyopathy by endomyocardial biopsy","volume":"18","author":"Mackay","year":"1994","journal-title":"Ultrastruct. Pathol."},{"key":"10.1016\/j.lfs.2025.123595_bb0035","first-page":"16739","article-title":"Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells","volume":"262","author":"Drake","year":"1987","journal-title":"Evidence for two forms of the enzyme, J Biol Chem."},{"key":"10.1016\/j.lfs.2025.123595_bb0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.32607\/actanaturae.11058","article-title":"Diversity and functions of type II topoisomerases","volume":"13","author":"Sutormin","year":"2021","journal-title":"Acta Nat."},{"key":"10.1016\/j.lfs.2025.123595_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092765","article-title":"TOP2B: the first thirty years","volume":"19","author":"Austin","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123595_bb0050","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add4920","article-title":"Untangling the roles of TOP2A and TOP2B in transcription and cancer","volume":"8","author":"Uuskula-Reimand","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.lfs.2025.123595_bb0055","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.lfs.2025.123595_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113480","article-title":"Anthracyclines as topoisomerase II poisons: from early studies to new perspectives","volume":"19","author":"Marinello","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123595_bb0065","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1021\/bi00309a013","article-title":"Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents","volume":"23","author":"Pommier","year":"1984","journal-title":"Biochemistry"},{"key":"10.1016\/j.lfs.2025.123595_bb0070","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.lfs.2025.123595_bb0075","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/01459740.1992.9966054","article-title":"Psychiatrist, traditional healer and culture integrated in clinical practice in Bali","volume":"13","author":"Suryani","year":"1992","journal-title":"Med. Anthropol."},{"key":"10.1016\/j.lfs.2025.123595_bb0080","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2025.123595_bb0085","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2025.123595_bb0090","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s12012-007-0023-3","article-title":"Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?","volume":"7","author":"Hasinoff","year":"2007","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.lfs.2025.123595_bb0095","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008209","article-title":"Clinically translatable prevention of anthracycline cardiotoxicity by dexrazoxane is mediated by topoisomerase II beta and not metal chelation","volume":"14","author":"Jirkovsky","year":"2021","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.lfs.2025.123595_bb0100","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1073\/pnas.91.5.1781","article-title":"Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp","volume":"91","author":"Roca","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.lfs.2025.123595_bb0105","doi-asserted-by":"crossref","first-page":"10629","DOI":"10.1073\/pnas.1832879100","article-title":"Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187","volume":"100","author":"Classen","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.lfs.2025.123595_bb0110","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1186\/1471-2407-14-842","article-title":"Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms","volume":"14","author":"Deng","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lfs.2025.123595_bb0115","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: state-of-the-art and future perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.lfs.2025.123595_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116281","article-title":"Comparison of human induced pluripotent stem-cell derived cardiomyocytes with human mesenchymal stem cells following acute myocardial infarction","volume":"9","author":"Citro","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2025.123595_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141176","article-title":"Evaluation of changes in morphology and function of human induced pluripotent stem cell derived cardiomyocytes (HiPSC-CMs) cultured on an aligned-nanofiber cardiac patch","volume":"10","author":"Khan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2025.123595_bb0130","doi-asserted-by":"crossref","first-page":"53451","DOI":"10.1021\/acsami.2c12575","article-title":"Modulation of mitochondrial bioenergetics by polydopamine nanoparticles in human iPSC-derived cardiomyocytes","volume":"14","author":"Alvi","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.lfs.2025.123595_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.567842","article-title":"Scalable biomimetic coaxial aligned nanofiber cardiac patch: a potential model for \u201cclinical trials in a dish\u201d","volume":"8","author":"Kumar","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.lfs.2025.123595_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/srep25333","article-title":"Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes","volume":"6","author":"Maillet","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2025.123595_bb0145","doi-asserted-by":"crossref","first-page":"556","DOI":"10.7150\/ijbs.29907","article-title":"Rosmarinic acid alleviates cardiomyocyte apoptosis via cardiac fibroblast in doxorubicin-induced cardiotoxicity","volume":"15","author":"Zhang","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.lfs.2025.123595_bb0150","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41418-019-0372-z","article-title":"FNDC5 alleviates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via activating AKT","volume":"27","author":"Zhang","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.lfs.2025.123595_bb0155","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13287-024-03792-3","article-title":"Bioorthogonal non-canonical amino acid tagging to track transplanted human induced pluripotent stem cell-specific proteome","volume":"15","author":"Sridharan","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.lfs.2025.123595_bb0160","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/cncr.10876","article-title":"Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma","volume":"95","author":"Vaskivuo","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.lfs.2025.123595_bb0165","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1369\/jhc.2009.954446","article-title":"Significance of increased apoptosis and Bax expression in human small intestinal adenocarcinoma","volume":"57","author":"Gao","year":"2009","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.lfs.2025.123595_bb0170","first-page":"356","article-title":"Expression and prognostic significance of bcl-2 and bax in the progression and clinical outcome of transitional bladder cell carcinoma","volume":"15","author":"Golestani Eimani","year":"2014","journal-title":"Cell J."},{"key":"10.1016\/j.lfs.2025.123595_bb0175","first-page":"325","article-title":"Bax\/Bcl-2 expression ratio in prediction of response to breast cancer radiotherapy, Iran J Basic","volume":"21","author":"Azimian","year":"2018","journal-title":"Med. Sci."},{"key":"10.1016\/j.lfs.2025.123595_bb0180","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.3892\/mmr.2015.3939","article-title":"Quantitative analysis of the mRNA expression levels of BCL2 and BAX genes in human osteoarthritis and normal articular cartilage: an investigation into their differential expression","volume":"12","author":"Karaliotas","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.lfs.2025.123595_bb0185","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbadis.2004.11.021","article-title":"Expression of cell survival\/death genes: Bcl-2 and Bax at the rate of colon cancer prognosis","volume":"1741","author":"Paul-Samojedny","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.lfs.2025.123595_bb0190","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/00001813-199607000-00011","article-title":"The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells","volume":"7","author":"Hasinoff","year":"1996","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.lfs.2025.123595_bb0195","unstructured":"C. Eneh, M.R. Lekkala, Dexrazoxane, in: StatPearls, (Treasure Island (FL))."},{"key":"10.1016\/j.lfs.2025.123595_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.594123","article-title":"Topoisomerase 2B decrease results in diastolic dysfunction via p53 and Akt: a novel pathway","volume":"7","author":"Moudgil","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.lfs.2025.123595_bb0205","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202201159","article-title":"Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis","volume":"221","author":"Eskandari","year":"2022","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.lfs.2025.123595_bb0210","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1568-1637(03)00026-6","article-title":"Caspases, apoptosis and aging","volume":"2","author":"Zhang","year":"2003","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.lfs.2025.123595_bb0215","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0531-5565(02)00013-X","article-title":"Age-associated increases in the activity of multiple caspases in Fisher 344 rat organs","volume":"37","author":"Zhang","year":"2002","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.lfs.2025.123595_bb0220","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.semcdb.2017.10.034","article-title":"Non-apoptotic Caspase regulation of stem cell properties","volume":"82","author":"Baena-Lopez","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.lfs.2025.123595_bb0225","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s44318-024-00163-9","article-title":"The caspase-activated DNase promotes cellular senescence","volume":"43","author":"Haimovici","year":"2024","journal-title":"EMBO J."},{"key":"10.1016\/j.lfs.2025.123595_bb0230","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.molcel.2015.01.018","article-title":"Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death","volume":"57","author":"Ichim","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.lfs.2025.123595_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101747","article-title":"Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP\/PKA\/SIRT1 pathway","volume":"37","author":"Hu","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.lfs.2025.123595_bb0240","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/cvr\/cvae077","article-title":"Isthmin-1 alleviates cardiac ischaemia\/reperfusion injury through cGMP-PKG signalling pathway","volume":"120","author":"Hu","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2025.123595_bb0245","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/toxsci\/kfae008","article-title":"Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage","volume":"198","author":"Kerestes","year":"2024","journal-title":"Toxicol. Sci."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525002292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525002292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T13:18:08Z","timestamp":1745327888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320525002292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":49,"alternative-id":["S0024320525002292"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2025.123595","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SiRNA-mediated knockdown of TOP2B protects hiPSC-derived cardiomyocytes from doxorubicin-induced toxicity","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2025.123595","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"123595"}}